{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:55:50Z","timestamp":1785419750975,"version":"3.56.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12328-022-01651-3","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T18:06:44Z","timestamp":1655834804000},"page":"818-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis"],"prefix":"10.1007","volume":"15","author":[{"given":"Tetsushi","family":"Azami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Yamawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Niiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Maruoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Nagahama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"1651_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100270","volume":"26","author":"S Nabeshima","year":"2021","unstructured":"Nabeshima S, Yamasaki M, Matsumoto N, et al. Atezolizumab-induced sclerosing cholangitis in a patient with lung cancer: a case report. Cancer Treat Res Commun. 2021;26: 100270.","journal-title":"Cancer Treat Res Commun"},{"key":"1651_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310.","journal-title":"Immunity"},{"key":"1651_CR3","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"1651_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020;26:353\u201365.","journal-title":"World J Gastroenterol"},{"key":"1651_CR5","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965\u201373.","journal-title":"Mod Pathol"},{"key":"1651_CR6","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/hep.31089","volume":"71","author":"L Stuart","year":"2020","unstructured":"Stuart L, Lambourne B, Turner P, et al. Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma. Hepatology. 2020;71:2164\u20136.","journal-title":"Hepatology"},{"key":"1651_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4251\/wjgo.v13.i2.147","volume":"13","author":"J Tang","year":"2021","unstructured":"Tang J, Zhao GX, Deng SS, et al. Rare common bile duct metastasis of breast cancer: a case report and literature review. World J Gastrointest Oncol. 2021;13:147\u201356.","journal-title":"World J Gastrointest Oncol"},{"key":"1651_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1084\/jem.20022235","volume":"198","author":"Y Iwai","year":"2003","unstructured":"Iwai Y, Terawaki S, Ikegawa M, et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med. 2003;198:39\u201350.","journal-title":"J Exp Med"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-022-01651-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-022-01651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T13:58:50Z","timestamp":1659016730000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-022-01651-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1651"],"URL":"https:\/\/doi.org\/10.1007\/s12328-022-01651-3","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"9 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wataru Ichikawa received an honorarium and grant from TAIHO Pharmaceutical and Chugai Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}